Research Article
Cerebrospinal Fluid Biomarkers in Spinocerebellar Ataxia: A Pilot Study
Table 1
Patient demographics.
| Patient demographics | | Control () | MSA-C () | SCA1 () | SCA2 () | SCA6 () |
| Gender (F/M) | 3/2 | 3/2 | 1/4 | 1/5 | 3/2 | Age (mean ± SEM) range | 50.8 ± 5.79 34–70 | 55.4 ± 1.50 50–59 | 52.0 ± 3.26 43–61 | 54.0 ± 1.85 49–59 | 53.4 ± 3.70 45–66 | Age at onset (mean ± SEM) range | | 47.2 ± 3.89 32–53 | 41.2 ± 1.59 38–47 | 32.7 ± 3.70 18–44 | 37.6 ± 5.35 25–55 | Symptom duration, years (mean ± SEM) range | | 8.2 ± 2.67 3–18 | 10.8 ± 2.22 4–15 | 23.6 ± 4.92 11–40 | 15.8 ± 2.58 11–25 | SARA score (0–40) (mean ± SEM) range | 0.375 ± 0.214 0-1 | 20.7 ± 5.12 8–39 | 11.1 ± 1.41 6–14.5 | 9.7 ± 1.23 6–13 | 15.9 ± 0.557 14–17.5 | Expanded CAG repeat size (mean ± SEM) range | | | 46 ± 1.58 42–50 | 37.5 ± 0.34 36–38 | 24 ± 1.29 21–27 |
|
|
Data are shown as mean (standard error). SARA score is a validated rating scale for the severity of ataxia ranging 0–40.
|